Bone Health Management for Women Diagnosed With Breast Cancer

March 23, 2017 updated by: Olivia Tseng, MD, University of British Columbia

Bone Health Management for Women Diagnosed With Breast Cancer: A Pilot Study

The purpose of this study is to test the feasibility of the study protocol. The study protocol was designed to evaluate questions - "Do educational materials improve dual x-ray absorptiometry (DXA) screening rates for women diagnosed with breast cancer" and "Does educational materials delivered by the participant's selected choice change DXA screening rates compared to the conventional mail method?".

Study Overview

Detailed Description

"Bone health management" for osteoporosis is important for women diagnosed with breast cancer. Osteoporosis can lead to bones breaking easily. Broken bones may make living independently challenging. Effective bone health management can reduce the risk of broken bones. This study will examine whether providing "osteoporosis information" to women diagnosed with breast cancer will promote their bone health management. With the current advance in technology, people are more interested in receiving information by email or smartphone text messaging. This study will also examine whether delivering osteoporosis information in different ways will change bone health management.

Study Type

Interventional

Enrollment (Actual)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1L3
        • BC Cancer Research Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 75 years (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women
  • Is 65-75 year old on July 1st, 2015
  • Lives in British Columbia (BC), Canada
  • Reads and understands the information provided in English
  • Was diagnosed with breast cancer prior to July 1st, 2012
  • Is not receiving surgery, radiation or chemotherapy for any cancers
  • Has not had breast cancer spread beyond her breast(s) and nearby lymph nodes
  • Has not had screening tests after July 1st, 2012
  • Is not taking medications prescribed by doctors for osteoporosis

Exclusion criteria:

  • Is medically unfit for preventive care (death, cognitive impairment, nursing home admission, severe mental illness, etc), which will be determined by their family doctors
  • Have terminated patient-doctor relationship with her family doctor who is indicated in our record

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Educational materials/mail
Participants in this group will receive educational materials by mail on the first day of the follow-up period.
Participants in this group will receive any educational materials by mail during hte follow-up period.
Experimental: Educational materials/participant choice
Participants in this group will receive educational materials by participant choice on the first day of the follow-up period.
Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
No Intervention: Control
Participants in this group will not receive any educational materials during hte follow-up period. Educational materials will be sent by mail after the completion of this study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
DXA screening rates
Time Frame: 6 months
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of participants diagnosed with osteoporosis
Time Frame: 6 months
6 months
Percentage of participants initiating osteoporosis medication
Time Frame: 6 months
6 months
Changes in Calcium in take
Time Frame: 6 months
measured as mg per week using validated questionnaires
6 months
Changes in vitamin D status
Time Frame: 6 months
measured as scores using validated questionnaires
6 months
Changes in exercise patterns
Time Frame: 6 months
measured as scores using validated questionnaires
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Martin Dawes, MD, PhD, University of British Columbia
  • Principal Investigator: John J. Spinelli, PhD, British Columbia Cancer Agency

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2015

Primary Completion (Actual)

February 20, 2017

Study Completion (Actual)

March 20, 2017

Study Registration Dates

First Submitted

June 12, 2015

First Submitted That Met QC Criteria

June 24, 2015

First Posted (Estimate)

June 29, 2015

Study Record Updates

Last Update Posted (Actual)

March 27, 2017

Last Update Submitted That Met QC Criteria

March 23, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Educational materials/mail

3
Subscribe